In the commercial insurance market there can be wide variation in the cost of a service, driven by negotiating tactics and leverage of providers versus health plans. One technique to help drive utilization toward the lower unit cost providers is reference pricing. In reference pricing, the insurer typically identifies a low-cost provider and creates a benefit design in the health plan that ties payment for the service to that low-cost provider. The member must pick up the difference in cost if they choose to use a higher-cost provider. The impact tends to be that other providers must lower their prices to maintain market share and that patients gravitate toward greater use of the low-cost suppliers to minimize their out-of-pocket spending. The tactic gained widespread attention when CalPERS began to use it on joint replacement surgeries. Now research in JAMA Internal Medicine examines use of reference pricing in connection with diagnostic testing. (Int. Med. Article) The authors compared a large company that used reference pricing for laboratory tests with comparable members who were not in a plan using the technique. The employer had set maximum reimbursement at 60% of the distribution range for testing prices and had made pricing data available to members on a mobile app. The change appears to have worked well, although no quality data was reported, so we don’t know if care was impacted, but that is doubtful in the case of lab testing. Members covered by reference pricing were more likely to use lower cost labs. By the third year, the average price paid had declined 32%. The employer saved around $1.5 million over the three years and the employees saved $1.05 million in out-of-pocket spending. Lab testing is a relatively small portion of overall spending, but you can imagine that if it were more broadly applied to health services and products and even 15-20% price reductions were seen, a substantial reduction in health spending could occur.
✅ Subscribe via Email
About this Blog
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
June 8, 2023
Yet Another Comprehensive Look at Lockdowns
Another major report finds that lockdowns had very little efficacy, in regard to infections or…
Commentary
June 7, 2023
More and More on Jobs Reports
More BLS machinations around jobs numbers, this time in regard to seasonal adjustments.
Commentary
June 7, 2023
Me on a Podcast
Your opportunity to see and hear me, courtesy of the Michele Tafoya podcast.